ESTRO 2024 - Abstract Book

S1616

Clinical - Lung

ESTRO 2024

4,970 stereotactic radiotherapy episodes for lung cancer were included in the analysis. During the study period, the total number of Trusts delivering curative stereotactic RT for lung cancer increased from 21 to 41 while the overall proportion of curative lung episodes delivered using stereotactic RT increased from 25% to 33%. The national proportion of these treatments delivered using IMRT/rotational IMRT varied from 88% to 97% during the study period. In the first half of 2022, the median proportion across the NHS Trusts was 99% (metric 1b). The national average interval between DTT/ECAD and treatment start for curative lung radiotherapy for the 16,835 included treatment episodes varied between 21 days in 2020 to 24 days in 2022 (metric 2). In the second half of 2022 the median interval across the NHS Trusts was 24 days. The results for all time periods are presented in Table 1.

Conclusion:

The use of IMRT/rotational IMRT for non-stereotactic curative lung cancer treatment increased across England between January 2020 and June 2022. For stereotactic curative lung cancer treatments, the median proportion of treatments using IMRT/rotational IMRT across all NHS Trusts was consistently above 99% during the study period.